Journal of Turkish Clinical Biochemistry

The official publication of Turkish Society of Clinical Biochemistry

Submit Your Research
Diamond OA
No APCs
First Decision
30 Days
Indexed In
TR Dizin
Original Research
December 01, 2008
JTCB. 2008 Dec 1; 6 (3) : 087-093
32 14
PDF (TÜRKÇE)

Serum ADMA and NO Levels in Chronic Obstructive Pulmonary Disease Patients

Said Sami Erdem1, Fikret Kanat2, Ali Ünlü3
1 Kars Doğum ve Çocuk Bakımevi Laboratuarı, Kars
2 Selçuk Üniversitesi, Meram Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Konya
3 Selçuk Üniversitesi, Meram Tıp Fakültesi, Biyokimya Anabilim Dalı, Konya

Abstract

Objective: The aim of our study was to determine serum ADMA, NO and arginine levels in patients with COPD.

Material and Methods: Seventy five COPD subjects participated in this study. To be selected patients had to have no other diseases. The control group was formed by twenty five appearentely healthy people. ADMA and argi nine levels were measured by high performance liquid chromatoghraphy with fluorecence detection. Plasma Nitrite/Nitrate concentrations were determined using a commercial colorimetric assay.

Results: Patients of COPD had significant higher values of ADMA (p<0.001), lower values of NO compared to control group (p:0.02). There was no difference between groups for arginine values (p:0.2), but the Arginine/ADMA ratio of COPD group was significantly different compared to control group (p:0.003).

Conclusion: Our study shows that plasma ADMA level is increased in the COPD patients. ADMA seems to be a possible new marker of prognosis of COPD. ADMA may play an important role in the progression of pulmonary hypertension in COPD patients. ADMA may therefore represent a novel therapeutic target for the treatment and prevention of pulmonary hypertension.

Keywords

Asymmetric dimethylarginine nitric oxide COPD

Citation

ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Erdem, Said Sami, Fikret Kanat, and Ali Ünlü. 2008. “Serum ADMA and NO Levels in Chronic Obstructive Pulmonary Disease Patients”. Journal of Turkish Clinical Biochemistry 6 (3):087-093. https://turkclinbiochem.org/index.php/pub/article/view/107.
Endnote/Zotero/Mendeley (RIS) BibTeX

Publish with JTCB

Diamond Open Access

Fully Diamond OA with no APCs and no submission fees. Your research is freely available to readers worldwide from the day it publishes.

30-Day First Decision

Double-blind peer review from an active editorial team returns a first decision in about 30 days, keeping your manuscript moving.

Global Platform

Backed by the Turkish Society of Clinical Biochemistry, JTCB welcomes submissions from researchers worldwide and reaches an international laboratory audience.

Focused Laboratory Scope

Method validation, analyzer comparisons, reference intervals, quality indicators, preanalytical studies, and instructive clinical case reports.

Credible and Discoverable

All manuscripts publish in English and follow ICMJE and COPE guidelines, with Crossref DOIs and TR Dizin indexing ensuring global discoverability.

© 2026 Journal of Turkish Clinical Biochemistry. All rights reserved.